FDA Regulations Align with Global QMSR Standards

For nearly three decades, the United States medical device industry operated under the Food and Drug Administration’s (FDA) Quality System Regulation (QSR), codified in 21 CFR Part 820. Established in 1996, the QSR served as the bedrock for ensuring medical devices were safely and consistently manufactured.

However, the regulatory landscape has changed. On February 2, 2026, the FDA officially retired the legacy QSR, replacing it with the Quality Management System Regulation (QMSR).

This landmark shift modernizes Part 820 by harmonizing U.S. requirements with global standards. For medical device manufacturers, this transition represents a profound philosophical and operational shift.

What is the Change and Why Did It Happen?

The core of the QMSR is the direct incorporation by reference of ISO 13485:2016 — reconfirmed by ISO until April, 2030 — the internationally recognized consensus standard for medical device quality management systems (QMS).

Why the Change?

Historically, medical device manufacturers selling products globally had to maintain dual quality systems. One would satisfy the FDA’s QSR and another would comply with ISO 13485 for international markets (such as the European Union, Canada, and Australia). Recognizing that the QSR and ISO 13485 are substantially similar in their safety and efficacy goals, the FDA enacted this transition to achieve:

• Global Harmonization: Reducing the regulatory burden on manufacturers by aligning U.S. regulations with the rest of the world.
• Reduced Duplication: Allowing companies to operate under a single, unified quality manual rather than running parallel compliance programs.
• Modernized Practices: Infusing modern, process-oriented, and risk-management-focused methodologies into U.S. regulatory oversight.

While the QMSR relies heavily on ISO 13485, the FDA has retained several U.S.-specific supplemental requirements to preserve existing statutory protections. This ranges from traceability for life-supporting and life-sustaining devices, to strict device labeling and packaging controls, to highly specific requirements to ensure traceability and inspection-readiness.

How QMSR Impacts Medical Device Companies

The transition from QSR to QMSR alters how quality systems are designed, operated, and audited.

Holistic Risk Management

Under the old QSR, formal risk analysis was largely restricted to design controls. Under QMSR, risk-based decision-making must permeate the entire product lifecycle and every aspect of the QMS. This means risk assessment must be factored into purchasing, supplier management, training, and manufacturing processes.

Elimination of FDA Inspection Exemptions

Historically, under 21 CFR 820.180(c), manufacturers were allowed to keep internal quality audits, management review reports, and supplier audit reports confidential during routine FDA inspections. Under the QMSR, this exemption is gone. FDA investigators now have the authority to review these documents during inspections to verify that the manufacturer is actively monitoring and correcting its own QMS.

A Brand-New Inspection Model

The FDA has retired the legacy quality system inspection technique. In its place, the FDA has implemented a new compliance program manual (CP 7382.850) that employs a risk-based, audit-style approach. Rather than checking compliance using rigid subsystem categories, FDA inspectors will evaluate six core quality management system areas (such as Change Control, Management Oversight, and Design) based on the risk profile of the specific device.

QSR vs. QMSR: At a Glance

Action Plan: What Companies Must Do to Remain Compliant

Now that the February 2, 2026 effective date has passed, any facility inspected by the FDA will be evaluated under the QMSR framework. Companies must take immediate, proactive steps to align with the new standard.

Conduct a Comprehensive Gap Analysis

Even if your organization is already certified to ISO 13485:2016, do not assume you are automatically compliant with QMSR. Perform a gap analysis mapping your current processes against the QMSR, with specific attention to the FDA’s U.S.-specific supplemental requirements (e.g., 21 CFR Part 803 for Medical Device Reporting and Part 830 for UDI).

Overhaul and Align Documentation

Update your Quality Manual and standard operating procedures (SOPs) to reference ISO 13485 clauses instead of old QSR subsections. Terminology should also align with the new keyword preferences. Transition concepts like the Device Master Record (DMR) and Design History File (DHF) into the ISO-preferred Medical Device File (MDF) structure.

Train Personnel on Risk-Based Lifecycles

Because QMSR shifts the focus from checking boxes to managing risk, staff must be educated on how to document and justify risk-based decisions in areas outside of design—such as supplier management, corrective and preventive actions (CAPA), and software validation.

Prepare for Open-Book FDA Inspections

Since internal audits, supplier evaluations, and management review records are no longer shielded from FDA eyes, audit readiness takes on a new meaning. Ensure that your internal audit reports are clear, objective, and demonstrate a robust commitment to continuous improvement. If an FDA inspector sees an issue in an internal audit, they will expect to see an active, well-documented path to resolution.

The transition to the Quality Management System Regulation marks a major milestone in medical device regulation. While adapting to QMSR requires an initial investment of time and resources to align documentation and train personnel, the long-term benefits are substantial.

By unifying international and domestic quality expectations, QMSR eliminates redundant oversight, elevates product quality, and ultimately accelerates the delivery of safe, innovative medical devices to the patients who rely on them.